Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib

Clinical Pharmacokinetics

Volumn 47, Issue 11, 2008, Pages 703-720

  Takemoto, Jody K ^a   Reynolds, Jonathan K ^a   Remsberg, Connie M ^a   Vega Villa, Karina R ^a   Davies, Neal M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cyclo oxygenase 2 inhibitors, pharmacodynamics; Cyclo oxygenase 2 inhibitors, pharmacokinetics; Etoricoxib, pharmacodynamics; Etoricoxib, pharmacokinetics; Nonsteroidal anti inflammatories, pharmacodynamics

Indexed keywords

ACETYLSALICYLIC ACID; ALGIX; ALUMINUM HYDROXIDE; CALCIUM CARBONATE; CARBOXYLIC ACID; CONJUGATED ESTROGEN; CYTOCHROME P450 3A4; DICLOFENAC; DIGOXIN; EQUILIN; ESTRONE; ETHINYLESTRADIOL; ETORICOXIB; GLUCURONIDE; IBUPROFEN; KETOCONAZOLE; MAGNESIUM HYDROXIDE; METHOTREXATE; MICONAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PREDNISOLONE; PREDNISONE; RIFAMPICIN; TAUXIB; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHROPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; LEG EDEMA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; THROMBOEMBOLISM; THROMBOSIS; TOOTH PAIN; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; HUMANS; KIDNEY FAILURE; LIVER FAILURE; OSTEOARTHRITIS; PAIN; PYRIDINES; SULFONES;

EID: 53549090447     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847110-00002     Document Type: Review

References (84)

1. Chauhan B, Shimpi S, Paradkar A. Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique. AAPS PharmSciTech 2005; 6 (3): E405-12
2. Zhou GX, Crocker L, Xu J, et al. In-line measurement of a drug substance via near infrared spectroscopy to ensure a robust crystallization process. J Pharm Sci 2006 Nov; 95 (11): 2337-47
3. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 Feb; 296 (2): 558-66
4. Dallob A, Hawkey CJ, Greenberg H, et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol 2003 Jun; 43 (6): 573-85
5. Agrawal NG, Porras AG, Matthews CZ, et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001 Oct; 41 (10): 1106-10
6. Rose MJ, Agrawal N, Woolf EJ, et al. Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS. J Pharm Sci 2002 Feb; 91 (2): 405-16
7. Agrawal NG, Porras AG, Matthews CZ, et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003 Mar; 43 (3): 268-76
8. Agrawal NG, Rose MJ, Matthews CZ, et al. Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol 2003 Oct; 43 (10): 1136-48
9. Rodrigues AD, Halpin RA, Geer LA, et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 2003 Feb; 31 (2): 224-32
10. Agrawal NG, Matthews CZ, Mazenko RS, et al. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol 2004 Oct; 44 (10): 1125-31
11. Matthews CZ, Woolf EJ, Lin L, et al. High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection. J Chromatogr B Biomed Sci Appl 2001 Feb 25; 751 (2): 237-46
12. Nageswara Rao R, Meena S, Raghuram Rao A. An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. J Pharm Biomed Anal 2005 Sep 15; 39 (3-4): 349-63
13. Brautigam L, Nefflen JU, Geisslinger G. Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. J Chromatogr 2003 May 25; 788 (2): 309-15
14. Brum Jr L, Fronza M, Ceni DC, et al. Validation of liquid chromatography and liquid chromatography/tandem mass spectrometry methods for the determination of etoricoxib in pharmaceutical formulations. J AOAC Int 2006 Sep-Oct; 89 (5): 1268-75
15. Werner U, Werner D, Hinz B, et al. A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. Biomed Chromatogr 2005 Mar; 19 (2): 113-8
16. Pavan Kumar VV, Vinu MC, Ramani AV, et al. Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. Biomed Chromatogr 2006 Jan; 20 (1): 125-32
17. Ramakrishna NV, Vishwottam KN, Wishu S, et al. Validated liquid chromatographic ultraviolet method for the quantitation of etoricoxib in human plasma using liquid-liquid extraction. J Chromatogr 2005 Feb 25; 816 (1-2): 215-21
18. Dalmora SL, da Silva Sangoi M, da Silva LM, et al. Validation of a capillary zone electrophoresis method for the comparative determination of etoricoxib in pharmaceutical formulations. J Sep Sci 2007 Dec 11; 31 (1): 169-76
19. Matthews CZ, Subramanian R, Woolf EJ, et al. Isolation and structural characterization of the photolysis products of etoricoxib. Pharmazie 2004 Dec; 59 (12): 913-9
20. Agrawal NG, Matthews CZ, Mazenko RS, et al. Pharmacokinetics of etoricoxib in patients with renal impairment. J Clin Pharmacol 2004 Jan; 44 (1): 48-58
21. Hynninen VV, Olkkola KT, Neuvonen PJ, et al. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. Eur J Clin Pharmacol. Epub 2008 Sep 9
22. Chauret N, Yergey JA, Brideau C, et al. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001 Apr 23; 11 (8): 1059-62
23. Kassahun K, McIntosh IS, Shou M, et al. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001 Jun; 29 (6): 813-20
24. Merck & Co, Inc. Arcoxia (etoricoxib) [prescribing information; online]. Available from URL: http://www.arcoxia.ae/secure/resources/pi/pi.html [Accessed 2008 Sep 3]
25. Schwartz JI, Agrawal NG, Kher UA, et al. Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib. J Clin Pharmacol 2007 Oct; 47 (10): 1342-6
26. Singh VP, Patil CS, Kulkarni SK. Analysis of interaction between etoricoxib and tramadol against mechanical hyperalgesia of spinal cord injury in rats. Life Sci 2006 Feb 9; 78 (11): 1168-74
27. Moraes BM, do Amaral BC, Morimoto MS, et al. Anti-inflammatory and analgesic actions of etoricoxib (an NSAID) combined with misoprostol. Inflammopharmacology 2007 Aug; 15 (4): 175-8
28. Schwartz JI, Agrawal NG, Hartford AH, et al. The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. J Clin Pharmacol 2007 May; 47 (5): 620-7
29. Medhi B, Sukhija M, Prakash A, et al. Effects of etoricoxib on the pharmacokinetics of phenytoin. Pharmacol Rep 2008 Mar-Apr; 60 (2): 233-7
30. Karjalainen MJ, Neuvonen PJ, Backman JT. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol 2008 Aug; 103 (2): 157-65
31. Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther 2004 May; 26 (5): 667-79
32. Castaneda-Hernandez G, Favari L, Hoyo-Vadillo C. Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. Arzneimittel-Forschung 1995 May; 45 (5): 585-9
33. Davies NM, Jamali F. Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: evidence of shift in the toxicity site. Pharm Res 1997 Nov; 14 (11): 1597-600
34. Giraudel JM, Diquelou A, Laroute V, et al. Pharmacokinetic/ pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol 2005 Nov; 146 (5): 642-53
35. Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 2005 Jul; 44 (7): 846-59
36. Torres-Lopez JE, Lopez-Munoz FJ, Castaneda-Hernandez G, et al. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat. J Pharmacol Exp Ther 1997 Aug; 282 (2): 685-90
37. Wright MR, Davies NM, Jamali F. Toxicokinetics of indomethacin-induced intestinal permeability in the rat. Pharmacol Res 1997 Jun; 35 (6): 499-504
38. Davies NM, Skjodt NM. Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach. Clin Pharmacokinet 2000 May; 38 (5): 377-92
39. Davies NM, Reynolds JK, Undeberg MR, et al. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. Exp Rev Neurother 2006 Nov; 6 (11): 1643-55
40. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004 Oct 29; 7 (3): 332-6
41. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006 Oct 4; 296 (13): 1619-32
42. Davies NM, Good RL, Roupe KA, et al. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? Not as easy as 1, 2, 3. J Pharm Pharm Sci 2004 Jul 9; 7 (2): 217-26
43. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996; 10 (1): 1-17
44. Yuan Y, Hunt RH. Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des 2007; 13 (22): 2237-47
45. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002 Sep 21; 325 (7365): 619
46. Bannwarth B, Berenbaum F. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Exp Opin Investig Drugs 2005 Apr; 14 (4): 521-33
47. Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2003; 42 (6): 545-56
48. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000 Mar; 38 (3): 225-42
49. Baraf HS. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr Pharm Des 2007; 13 (22): 2228-36
50. Niederberger E, Manderscheid C, Geisslinger G. Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochem Biophys Res Commun 2006 Apr 14; 342 (3): 940-8
51. Maier TJ, Tausch L, Hoernig M, et al. Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol 2008 Oct 1; 76 (7): 862-72
52. Yang SF, Hsieh YS, Lue KH, et al. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. Clin Biochem 2008 Jan; 41 (1-2): 109-16
53. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006 Nov 18; 368 (9549): 1771-81
54. Malmstrom K, Kotey P, Coughlin H, et al. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain 2004 May-Jun; 20 (3): 147-55
55. Malmstrom K, Ang J, Fricke JR, et al. The analgesic effect of etoricoxib relative to that of acetaminophen analgesics: a randomized, controlled single-dose study in acute dental impaction pain. Curr Med Res Opin 2005 Jan; 21 (1): 141-9
56. Chang DJ, Desjardins PJ, King TR, et al. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial [published erratum appears in Anesth Analg 2005; 101 (3): 644]. Anesth Analg 2004 Sep; 99 (3): 807-15
57. Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002 Sep; 41 (9): 1052-61
58. Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord 2005; 6: 58
59. Zacher J, Feldman D, Gerli R, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19 (8): 725-36
60. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18 (2): 49-58
61. Reginster JY, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 2007 Jul; 66 (7): 945-51
62. Wiesenhutter CW, Boice JA, Ko A, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clinic Proc 2005 Apr; 80 (4): 470-9
63. Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30mg and ibuprofen 2400mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage 2007 Dec; 15 (12): 1348-56
64. Curtis SP, Losada B, Bosi-Ferraz M, et al. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients. Arthritis Rheum 2003; 48 Suppl.: s125
65. Bingham III CO, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007 Mar; 46 (3): 496-507
66. Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002 May 22; 3: 10
67. Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002 Aug; 29 (8): 1623-30
68. Schumacher Jr HR, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002 Jun 22; 324 (7352): 1488-92
69. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120mg once daily compared with indomethacin 50mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004 Feb; 50 (2): 598-606
70. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 Mar 17; 352 (11): 1092-102
71. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 Mar 17; 352 (11): 1071-80
72. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 Mar 17; 352 (11): 1081-91
73. Andersohn F, Schade R, Suissa S, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006 Jul; 37 (7): 1725-30
74. Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007 Feb 10; 369 (9560): 465-73
75. Baraf HS, Fuentealba C, Greenwald M, et al.; EDGE Study Group. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007 Feb; 34 (2): 408-20
76. Krueger K, Lino L, Dore R, et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) [published erratum appears in Ann Rheum Dis 2008 May; 67 (5): 732]. Ann Rheum Dis 2008 Mar; 67 (3): 315-22
77. Cannon CP, Curtis SP, Bolognese JA, et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006 Aug; 152 (2): 237-45
78. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001 Aug 9; 345 (6): 433-42
79. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8
80. Watson DJ, Bolognese JA, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004 Dec; 20 (12): 1899-908
81. Ramey DR, Watson DJ, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005 May; 21 (5): 715-22
82. Schwartz JI, Thach C, Lasseter KC, et al. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. J Clin Pharmacol 2007 Dec; 47 (12): 1521-31
83. Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004 Jan; 26 (1): 70-83
84. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost 2006 Oct; 96 (4): 393-400